Section Reviews: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthnlis: Pharmacological approaches to correct the bioelectric deficits in cystic fibrosis

References to Primarv Literature

• FEEL S, FITZSIMMONS S, SCHIDLOW D: Evolving demo-graphics of cystic fibrosis. Sem. Res, Crit. Care Med. (1994) 15(5).349–355.
   Web of Science ®Google Scholar
• FITZSIMMONS S: The changing epidemiology of cysticfibrosis. J. Fed. (1993) 122(1):1–9.
   Google Scholar
• GLASER V, ANSELL J: Therapeutic advances in cysticfibrosis. Spectrum (1994) 63:1–18.
   Google Scholar
• KEREM B, ROMMENS J, BUCHANAN J et al.: Identification of the cystic fibrosis gene: Genetic analysis. Science (1989) 245:1073–1080.
   PubMed Web of Science ®Google Scholar
• QUINTON PM: Cystic fibrosis: A disease in electrolyte transport. FASEBJ. (1990) 4:2709–2717.
   PubMed Web of Science ®Google Scholar
• RIORDAN J, ROMMENS J, KEREM B et al.: Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science (1989) 245:1066–1072.
   PubMed Web of Science ®Google Scholar
• ROMMENS J, IANNUZZI M, KEREM B et al.: Identification of the cystic fibrosis gene: chromosome walking and jumping. Science (1989) 245:1059–1065.
   PubMed Web of Science ®Google Scholar
• WELSH M: Abnormal regulation of ion channels in cystic fibrosis epithelia. FASEB J. (1990) 4:2718–2725.
   PubMed Web of Science ®Google Scholar
• KNOWLES MR, GATZY .1, BOUCHER RC: Increase bioelec-tric potential difference across respiratory epithelia in cystic fibrosis. New Engl. J. Med. (1981) 305:1489–1495.
   PubMed Web of Science ®Google Scholar
• BOUCHER RC, STUTTS MJ, KNOWLES MR, CANTLEY L, GATZY JT: Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adeny-late cyclase activation. J. Clin. Invest. (1986) 78:1245–1252.
   Google Scholar
• TOMKLEWICZ RP, APP EM, ZAYAS JG et al.: Amiloride Inhalation therapy in cystic fibrosis: influence on ion content, hydration and rheology of sputum. Am. Rev. Respir. Dis. (1993) 148:1002–1007.
   PubMed Web of Science ®Google Scholar
• APP EM, KING M, HELFESREIDER R, KOHLER D, MATTHYS H: Acute and long-term amiloride inhalation in cystic fibrosis lung disease: a rational approach to cystic fibrosis therapy. Am. Rev. Respir. Dis. (1990) 141:605–612.
   PubMed Web of Science ®Google Scholar
• siurrs MJ, CANESSA CM, OLSEN JC et al.: CFTR as a cAMP-dependent regulator of sodium channels. Science (1995) 269:847–850.
   PubMed Web of Science ®Google Scholar
• SMITH JJ, TRAVIS SM, GREENBURG EP, WELSH MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell (1996) 85:1–8,
   PubMedGoogle Scholar
• PIER GB, GROUT M, ZAIDI TS et al.: Role of mutant CFTR in hyper-susceptibility of cystic fibrosis patients to lung infections. Science (1996) 271:64–67.
   PubMed Web of Science ®Google Scholar
• KNOWLES MR, HOHNEKER KW, ZHOU Z et al.: A control-led study of adenoviral-vector-mediated gene transfer In the nasal epithelium of patients with cystic fibrosis. New Engl. J. Med. (1995) 333:823–831.
   PubMed Web of Science ®Google Scholar
• ZABNER J, RAMSEY BW, MEEKER DP et al.: Repeat admini-stration of an adenovirus vector encoding cystic fibro-sis transmembrane conductance regulator of the nasal epithelium of patients with cystic fibrosis. J. Clin. Invest. (1996) 97(6):1504–1511.
   PubMed Web of Science ®Google Scholar
• BROWN CR, HONG-BROWN LQ, BIWERSI J et al.: Glyceroltreatments result in the proper processing and function of the CFTR protein. Ninth Annual North American Cystic Fibrosis Conference: Late Breaking Science Abstracts (1995):820.6.
   Google Scholar
• HOWARD M, FRIZZELL RA, BEDWELL DM: Aminogly-coside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Med. (1996) 2:467–469.
   PubMed Web of Science ®Google Scholar
• CUMNG GR: Spectrum of mutations in cystic fibrosis. J. Bioenog. Biomembr. (1993) 25:7–10.
   PubMed Web of Science ®Google Scholar
• SHOSHANI T et al.: Association of a non-sense mutation (W1282X), the most common mutation in the AshkenaziJewish cystic fibrosis patients in Israel, with presentation of severe disease. Am. j. Hum. Genet. (1992) 50:222–228.
   PubMed Web of Science ®Google Scholar
• RAMSEY BW, ASTLEY SJ, AITKEN ML et al.: Efficacy and safety of short-term administration of aerosolized re-combinant human deoxyribonuclease in patients with cystic fibrosis. Am. Rev. Respir. Dis. (1993) 148:145–151.
   PubMed Web of Science ®Google Scholar
• FUCHS HJ, BOROWITZ DS, CHRISTIANSEN DTI et al.: Effect of aerosolized recombinant human DNase on exacer-bations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New Engl.J. Med. (1994) 331:637–642.
   PubMed Web of Science ®Google Scholar
• LAUBE BL, AUCI RM, SHILDS DE et al.: Effects of rhDNase on airflow obstruction and mucodhAry clearance in cystic fibrosis. Am.J. Respir. Crit. Care Med. (1996) 153:752–760.
   PubMed Web of Science ®Google Scholar
• KLEYMAN TR, CRAGOE EJ, Jr.: Amiloride and its analogsas tools in the study of ion transport. J. Membrane Biol (1988) 105:1–21.
   Google Scholar
• SIMCHOWITZ L, KLEYMAN TR, CRAGOE EJ, Jr.: An over-view of the structure-activity relations in the amiloride series. In: Amiloride and Its Analogs. Unique Cation Trans-port Inhibitors. Cragoe EJ, Jr., Kleyman TR, Simchowitz L (Eds.), VCH Publishers, New York (1992):9–24.
   Google Scholar
• KOHLER D, APP E, SCHMITZ-SCUMANN M, WURTEMBER-GER G, MATTHYS H: Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibrosis. Fur. J. Respir. Dis. (1986) 69\(Suppl. 146):319–326.
   Google Scholar
• KNOWLES MR, CHURCH NL, WALTNER WE et al.: A pilotstudy of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. New Engl. J. Med. (1990) 322:1189–1194.
   PubMed Web of Science ®Google Scholar
• ROLFE MW, KUNKEL SF, ROWENS B et al.: Suppression ofhuman alveolar macrophage-derived cytokines by amiloride. Am. J. Respir. Cell Mol. Biol. (1992) 6:576–582.
   PubMed Web of Science ®Google Scholar
• GALLO RU Aerosolized amiloride for the treatment oflung disease in cystic fibrosis [Letter]. New Engl. J. Med. (1990) 323:996–997.
   PubMed Web of Science ®Google Scholar
• KNOWLES MR, CHURCII NL, WALTNER WE et al.: Aerosol-ized amiloricie for the treatment of lung disease in cystic fibrosis [Letter]. New Engl. J. Med. (1990) 323:997–998.
   Web of Science ®Google Scholar
• PONS G, MARCHAND M, FOUCARD C et al.; THE AMILO-RIDE-AFLM COLLABORATIVE STUDY GROUP: French multicenter randomized double-blind placebo-control-led trial on nebulized amiloride in cystic fibrosis pa-tients. Cystic Fibrosis Conference Abstracts (1995):233–234.
   Google Scholar
• KNOWLES MR, CLARKE LL, BOUCHER RC: Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. New Engl. J. Med. (1991) 325:533–538.
   PubMed Web of Science ®Google Scholar
• MASON SJ, PARADISO AM, BOUCHER RC: Regulation of transepithelial ion transport and extracellular ATP in human normal and cystic fibrosis airway epithelium. Br. J. Pharmacol. (1991) 103:1649–1656.
   PubMed Web of Science ®Google Scholar
• BENALI R, PIERROT D, ZAHM JM, DE BENTZMANN S, PUCHELL E: Effect of extracelhilk,r ATP and UTP on fluid transport by human nasal epithelial cells in culture. Am. J. Respir. Cell. Mol. Biol. (1994) 10:363–368.
   PubMed Web of Science ®Google Scholar
• JIANG C, FINKBEINER WE, WIDDECOMBE JA, MCCRAY PB JR, MILLER SS: Altered fluid transport across airway epithelium in cystic fibrosis. Science (1993) 262:424–427.
   PubMed Web of Science ®Google Scholar
• DRUTZ D, SIIAFFER C, LACROIX K, JACOBUS K: Uridine 5'-triphosphate (UTP) regulates mucociliary clearance via purinergic receptor activation. Purine 1996 Molecu-lar, Pharmacological & Therapeutic Advances. Abstract, In press.
   Google Scholar
• DRUTZ D, SHAFFER C, LACROIX K et al.: Uridine triphosphate (UTP) regulates mucocillnry clearance via purinergic receptor activation. Drug Dev. Res. (1996) 37:185.
   Google Scholar
• LETHEM MI, DOWELL ML, VAN SCOTT M et al.: Nucleotideregulation of goblet cells in human airway epithelial explants: Normal exoeytosis in cystic fibrosis. Am. J. Respir. Cell. Mol. Biol. (1993) 9:315–322.
   Google Scholar
• DUBYAK GR, COWEN D, MEULLER LM: Activation of inositol phospholipid breakdown in lil.60 cells by P2-purinergic receptors for extracellular ATP. Evidence for mediation by both pertussis toxin-sensitive and pertussis toxin-insensitive mechanisms. J. Biol. Chem. (1988) 263:18108–18117.
   Google Scholar
• FINE J, COLE P, DAVIDSON JS: Extracellular nucleotides stimulate receptor-mediated calcium mobilization and inositol phosphate production in human fibroblasts. Biochem. J. (1989) 263:371–376.
   PubMed Web of Science ®Google Scholar
• STUTCHFIELD J, COCKCROFT S: Undifferentiated 11L-60 cells respond to extracellular ATP and UTP by stimulat-ing phospholipase C activation and exocytosis. FEBS Lett. (1990) 262 :256–258 .
   PubMed Web of Science ®Google Scholar
• BROWN HA, LAZAROWSKI ER, BOUCHER RC, HARDEN TK:Evidence that UTP and ATP regulate phospholipase C through a common extracellular 5'-nucleotide receptor in human airway epithelial cells. Mol. Pharrnacol. (1991) 40: 648–655.
   PubMed Web of Science ®Google Scholar
• LERMAN BB, BELARDINELLI L: Cardiac electrophysiologyof adenosine: basic and clinical concepts. Circulation. (1991) 83:1499–1509.
   PubMed Web of Science ®Google Scholar
• RODEN DM: Chapter 35. Antiarrhythmic drugs. In: Good-man and Gilman 's The Pharmacological Basis of therapeu-tics, 9th Edition. Hardman JC, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (Eds.), McGraw Hill, New York (1996):839–874.
   Google Scholar
• OLIVIER KN, BENNETT WD, GEARY CA et at Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate ± amiloride hi normal human adults. Am. Rev. Resp. Crit. Care Med. In press.
   Google Scholar
• GUAY-BRODER C, JACOBSON KA, BARNOY S et al.: Al receptor antagonist 8-cyclopenty1-1,3-dipropylxan-thine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator AF508 muta-tion. Biochemistry (1995) 34:9079–9087.
   PubMedGoogle Scholar
• CASAVOLA V, TURNER RJ, GUAY-BRODER C et al.: CPX, a selective At adenosine receptor antagonist, regulates Intracellular pH in cystic fibrosis cells. Am. J. Physiol. (1995) 269:C226–C233.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, GUAY-BRODER C, VAN GALEN PJ et al.: Stimulation by alkylxanthines of chloride efflux in CFPAC cells does not involve Al adenosine receptors. Biochemistry (1995) 34:9088–9094.
   Google Scholar
• BENNETT WI), OLIVIER KN, ZEMAN KL, et al.: Effects of aerosolized uridine 5'-triphosphate (UTP) plus amilo-ride on mucocillary clearance in adult patients with cystic fibrosis. Am. Rev. Resp. Crit. Care Med. In press.
   Google Scholar